 Sodium-Glucose Transporter 2
"Sodium-Glucose Transporter 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A sodium-glucose transporter that is expressed in the luminal membrane of the PROXIMAL KIDNEY TUBULES.
| Descriptor ID |
D051297
|
| MeSH Number(s) |
D12.776.157.530.450.625.437.750 D12.776.157.530.500.750.750 D12.776.543.585.450.625.562.750 D12.776.543.585.500.750.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sodium-Glucose Transporter 2".
Below are MeSH descriptors whose meaning is more specific than "Sodium-Glucose Transporter 2".
This graph shows the total number of publications written about "Sodium-Glucose Transporter 2" by people in UAMS Profiles by year, and whether "Sodium-Glucose Transporter 2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2021 | 1 | 1 | 2 | | 2020 | 0 | 1 | 1 | | 2019 | 1 | 0 | 1 | | 2017 | 0 | 1 | 1 | | 2016 | 0 | 2 | 2 | | 2015 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Sodium-Glucose Transporter 2" by people in Profiles over the past ten years.
-
Abu-Qaoud MR, Kumar A, Tarun T, Abraham S, Ahmad J, Khadke S, Husami R, Kulbak G, Sahoo S, Januzzi JL, Neilan TG, Baron SJ, Martin D, Nohria A, Reynolds MR, Kosiborod M, Dani SS, Ganatra S. Impact of SGLT2 Inhibitors on AF Recurrence After Catheter Ablation in?Patients With Type 2 Diabetes. JACC Clin Electrophysiol. 2023 10; 9(10):2109-2118.
-
Perazella MA, Juncos LA. Drug-Induced Osmotic Nephropathy: Add SGLT2-Inhibitors to the List? Kidney360. 2022 03 31; 3(3):550-553.
-
Norgard NB, Lopez-Candales A. The rise of SGLT2 inhibitors: the time is now for cardiovascular specialists to lead the charge. Postgrad Med. 2022 01; 134(1):11-13.
-
Hughes CB, Mussman GM, Ray P, Bunn RC, Cornea V, Thrailkill KM, Fowlkes JL, Popescu I. Impact of an SGLT2-loss of function mutation on renal architecture, histology, and glucose homeostasis. Cell Tissue Res. 2021 May; 384(2):527-543.
-
Thrailkill KM, Bunn RC, Uppuganti S, Ray P, Garrett K, Popescu I, Pennings JS, Fowlkes JL, Nyman JS. Genetic ablation of SGLT2 function in mice impairs tissue mineral density but does not affect fracture resistance of bone. Bone. 2020 04; 133:115254.
-
Reyes-Pardo H, Bautista R, Vargas-Robles H, Rios A, S?nchez D, Escalante B. Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage. BMC Nephrol. 2019 08 02; 20(1):292.
-
Cha SA, Park YM, Yun JS, Lim TS, Song KH, Yoo KD, Ahn YB, Ko SH. A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes. Lipids Health Dis. 2017 Apr 13; 16(1):58.
-
Saad M, Mahmoud AN, Elgendy IY, Abuzaid A, Barakat AF, Elgendy AY, Al-Ani M, Mentias A, Nairooz R, Bavry AA, Mukherjee D. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials. Int J Cardiol. 2017 Feb 01; 228:352-358.
-
Thrailkill KM, Nyman JS, Bunn RC, Uppuganti S, Thompson KL, Lumpkin CK, Kalaitzoglou E, Fowlkes JL. The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes. Bone. 2017 Jan; 94:141-151.
-
Thrailkill KM, Clay Bunn R, Nyman JS, Rettiganti MR, Cockrell GE, Wahl EC, Uppuganti S, Lumpkin CK, Fowlkes JL. SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice. Bone. 2016 Jan; 82:101-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|